Skip to Main Content
CKG
Home
Home
Home
TKG
Author details
Breadcrumb
Author Details
Full Name
Melissa Paoloni
Affiliation
Center for Cancer Research, National Cancer Institute
ORCID
Career Start Year
2002
Papers
28
H Index
23
Expertise
CM4AI Collaborator
PMID
Paper Title
Journal Title
Published Year
34741023
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2<sup>+</sup> breast cancer in the adaptively randomized I-SPY2 trial.
Nat Commun
2021
34741023
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2<sup>+</sup> breast cancer in the adaptively randomized I-SPY2 trial.
Nat Commun
2021
34611148
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.
NPJ Breast Cancer
2021
34611148
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.
NPJ Breast Cancer
2021
32701140
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
JAMA Oncol
2020
32031889
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
J Clin Oncol
2020
32701140
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
JAMA Oncol
2020
32031889
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
J Clin Oncol
2020
30061364
NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.
Clin Cancer Res
2018
30061364
NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.
Clin Cancer Res
2018
28948212
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.
NPJ Breast Cancer
2017
28948212
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.
NPJ Breast Cancer
2017
26866698
A Comparative Oncology Study of Iniparib Defines Its Pharmacokinetic Profile and Biological Activity in a Naturally-Occurring Canine Cancer Model.
PLoS One
2016
26866698
A Comparative Oncology Study of Iniparib Defines Its Pharmacokinetic Profile and Biological Activity in a Naturally-Occurring Canine Cancer Model.
PLoS One
2016
26728411
Neoadjuvant as Future for Drug Development in Breast Cancer--Response.
Clin Cancer Res
2016
27406347
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
N Engl J Med
2016
27406346
Adaptive Randomization of Neratinib in Early Breast Cancer.
N Engl J Med
2016
27406347
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
N Engl J Med
2016
27406346
Adaptive Randomization of Neratinib in Early Breast Cancer.
N Engl J Med
2016
26728411
Neoadjuvant as Future for Drug Development in Breast Cancer--Response.
Clin Cancer Res
2016
25712686
The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.
Clin Cancer Res
2015
25712686
The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.
Clin Cancer Res
2015
26091536
Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant Melanoma.
PLoS One
2015
26352142
Comparative Gene Expression Analyses Identify Luminal and Basal Subtypes of Canine Invasive Urothelial Carcinoma That Mimic Patterns in Human Invasive Bladder Cancer.
PLoS One
2015
26352142
Comparative Gene Expression Analyses Identify Luminal and Basal Subtypes of Canine Invasive Urothelial Carcinoma That Mimic Patterns in Human Invasive Bladder Cancer.
PLoS One
2015
26091536
Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant Melanoma.
PLoS One
2015
24637659
Prospective molecular profiling of canine cancers provides a clinically relevant comparative model for evaluating personalized medicine (PMed) trials.
PLoS One
2014
24637659
Prospective molecular profiling of canine cancers provides a clinically relevant comparative model for evaluating personalized medicine (PMed) trials.
PLoS One
2014
24803583
Toward a drug development path that targets metastatic progression in osteosarcoma.
Clin Cancer Res
2014
24803583
Toward a drug development path that targets metastatic progression in osteosarcoma.
Clin Cancer Res
2014
21655323
A compendium of canine normal tissue gene expression.
PLoS One
2011
21655323
A compendium of canine normal tissue gene expression.
PLoS One
2011
20621714
The creation of the Comparative Oncology Trials Consortium Pharmacodynamic Core: Infrastructure for a virtual laboratory.
Vet J
2010
20806871
Computed tomography characteristics of canine tracheobronchial lymph node metastasis.
Vet Radiol Ultrasound
2010
20621714
The creation of the Comparative Oncology Trials Consortium Pharmacodynamic Core: Infrastructure for a virtual laboratory.
Vet J
2010
20543980
Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs.
PLoS One
2010
20806871
Computed tomography characteristics of canine tracheobronchial lymph node metastasis.
Vet Radiol Ultrasound
2010
20543980
Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs.
PLoS One
2010
19330034
Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature.
PLoS One
2009
19330034
Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature.
PLoS One
2009
19823573
The Comparative Oncology Trials Consortium: using spontaneously occurring cancers in dogs to inform the cancer drug development pathway.
PLoS Med
2009
20028558
Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression.
BMC Genomics
2009
20028558
Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression.
BMC Genomics
2009
19823573
The Comparative Oncology Trials Consortium: using spontaneously occurring cancers in dogs to inform the cancer drug development pathway.
PLoS Med
2009
17981480
Inhibition of canine telomerase in vitro and in vivo using RNAi: further development of a natural canine model for telomerase-based cancer therapies.
Vet J
2008
17981480
Inhibition of canine telomerase in vitro and in vivo using RNAi: further development of a natural canine model for telomerase-based cancer therapies.
Vet J
2008
18202698
Translation of new cancer treatments from pet dogs to humans.
Nat Rev Cancer
2008
18202698
Translation of new cancer treatments from pet dogs to humans.
Nat Rev Cancer
2008
17338159
CCNU for the treatment of dogs with histiocytic sarcoma.
J Vet Intern Med
2007
17950880
Comparative oncology today.
Vet Clin North Am Small Anim Pract
2007
1 - 50 of 56
Column Actions
Search
Recommended Authors
Zhengming Chen
Weill Cornell Medicine and New York Presbyterian Hospital
Career Start Year
2013
Number of shared co-authors
0
Amanda P Beck
New York Medical College
Career Start Year
2012
Number of shared co-authors
0
Minhyung Kim
Roswell Park Comprehensive Cancer Center
Career Start Year
2010
Number of shared co-authors
0
Arun S Singh
University of California-Los Angeles
Career Start Year
2006
Number of shared co-authors
0
Cheryl Crozier
Ontario Institute for Cancer Research
Career Start Year
2006
Number of shared co-authors
1
Jessica A Bertout
Fred Hutchinson Cancer Research Center
Career Start Year
2006
Number of shared co-authors
0
Shubham Pant
The University of Texas MD Anderson Cancer Center
Career Start Year
2005
Number of shared co-authors
1
Stacey J Adam
Foundation for the National Institutes of Health
Career Start Year
2004
Number of shared co-authors
2
Vicky S Sabine
University of Guelph
Career Start Year
2004
Number of shared co-authors
0
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Career Start Year
2002
Number of shared co-authors
1
Saravut J Weroha
Mayo Clinic
Career Start Year
2001
Number of shared co-authors
5
Annette T Byrne
Royal College of Surgeons in Ireland (RCSI)
Career Start Year
1999
Number of shared co-authors
2
David J Liewehr
Center for Cancer Research
Career Start Year
1999
Number of shared co-authors
6
Thomas J George
UF Health Cancer Center
Career Start Year
1998
Number of shared co-authors
0
Lillian L Siu
Princess Margaret Cancer Centre, University Ave
Career Start Year
1995
Number of shared co-authors
1
Udo Rudloff
Center for Cancer Research, National Cancer Institute
Career Start Year
1994
Number of shared co-authors
4
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year
1994
Number of shared co-authors
5
Melania Pintilie
Princess Margaret Cancer Centre, University Health Network
Career Start Year
1993
Number of shared co-authors
0
Vera J Suman
Mayo Clinic
Career Start Year
1992
Number of shared co-authors
4
Sarah M Dry
Jonsson Comprehensive Cancer Center, University of California los angeles
Career Start Year
1992
Number of shared co-authors
0
Paul T Fanta
University of California San Diego Moores Cancer Center
Career Start Year
1992
Number of shared co-authors
2
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Career Start Year
1990
Number of shared co-authors
7
Joan Albanell
Hospital del Mar Research Institute
Career Start Year
1990
Number of shared co-authors
0
Emile E Voest
The Netherlands Cancer Institute
Career Start Year
1989
Number of shared co-authors
6
Luc Dirix
GZA Ziekenhuizen Campus Sint-Augustinus, University of Antwerp
Career Start Year
1988
Number of shared co-authors
1
Kenneth R Hess
The University of Texas MD Anderson Cancer Center
Career Start Year
1986
Number of shared co-authors
1
Seth M Steinberg
Center for Cancer Research, National Cancer Institute
Career Start Year
1984
Number of shared co-authors
17
Jeffrey S Ross
Foundation Medicine
Career Start Year
1974
Number of shared co-authors
0
Antonio Jimeno
University of Colorado School of Medicine
Career Start Year
1974
Number of shared co-authors
0
Dennis J Slamon
David Geffen School of Medicine at university of california los angeles
Career Start Year
1973
Number of shared co-authors
4
row(s) 1 - 30 of 30
Collaborators
Chand Khanna
National Cancer Institute, National Institutes of Health
Co-authored papers
13
Donald A Berry
MD Anderson Cancer Center
Co-authored papers
9
Christina Yau
University of California San Francisco
Co-authored papers
8
Laura J Van't Veer
University of California San Francisco
Co-authored papers
8
William F Symmans
Co-authored papers
8
Susan E Lana
College of Veterinary Medicine and Biomedical Sciences, Colorado State University
Co-authored papers
7
Rita Nanda
Co-authored papers
7
Judy C Boughey
Mayo Clinic
Co-authored papers
7
Claudine Isaacs
Co-authored papers
7
Teresa Helsten
Moores Cancer Center, University of California San Diego
Co-authored papers
5
Richard B Schwab
Department of Medicine and Moores Cancer Center, University of California San Diego
Co-authored papers
5
Scott M Berry
University of Kansas Medical Center
Co-authored papers
4
Minetta C Liu
Co-authored papers
4
Emanuel F Petricoin
Center for Applied Proteomics and Molecular Medicine, George Mason University
Co-authored papers
4
Denise M Wolf
University of California San Francisco
Co-authored papers
4
Lajos Pusztai
Co-authored papers
4
Stephen J Withrow
College of Veterinary Medicine and Biomedical Sciences, Colorado State University
Co-authored papers
3
Rachel L Yung
University of Washington
Co-authored papers
2
Paul S Meltzer
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers
2
Michael Hogarth
university of california san diego
Co-authored papers
2
Larissa A Korde
Clinical Investigations Branch, National Cancer Institute
Co-authored papers
2
Paul Haluska
Mayo Clinic
Co-authored papers
2
Wadih Arap
Rutgers Cancer Institute of New Jersey
Co-authored papers
1
Glenn Merlino
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers
1
Malcolm A Smith
National Cancer Institute
Co-authored papers
1
Tesa M Severson
Oncode Institute, The Netherlands Cancer Institute
Co-authored papers
1
Luca Sangiorgi
Department of Rare Skeletal Disorders - IRCCS Istituto Ortopedico Rizzoli
Co-authored papers
1
Ossama Tawfik
University of Kansas
Co-authored papers
1
Yves Pommier
Center for Cancer Research, National Cancer Institute
Co-authored papers
1
Donald A Barkauskas
Keck School of Medicine of the University of Southern California
Co-authored papers
1
1 - 30